Aliskiren + Placebo to Aliskiren + Hydrochlorothiazide (HCTZ) + Placebo to Hydrochlorothiazide (HCTZ) + Ramipril
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-diabetic Nephropathy
Conditions
Non-diabetic Nephropathy
Trial Timeline
Jan 1, 2011 → Dec 1, 2011
NCT ID
NCT01302899About Aliskiren + Placebo to Aliskiren + Hydrochlorothiazide (HCTZ) + Placebo to Hydrochlorothiazide (HCTZ) + Ramipril
Aliskiren + Placebo to Aliskiren + Hydrochlorothiazide (HCTZ) + Placebo to Hydrochlorothiazide (HCTZ) + Ramipril is a phase 2 stage product being developed by Novartis for Non-diabetic Nephropathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT01302899. Target conditions include Non-diabetic Nephropathy.
What happened to similar drugs?
2 of 3 similar drugs in Non-diabetic Nephropathy were approved
Approved (2) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01302899 | Phase 2 | Terminated |
Competing Products
3 competing products in Non-diabetic Nephropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Qutenza + Pregabalin | Astellas Pharma | Approved | 43 |
| Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg | AstraZeneca | Approved | 43 |
| Finerenone (BAY94-8862) + Placebo | Bayer | Phase 3 | 37 |